Older participants are frequently excluded from Parkinson's disease research
Introduction
Parkinson's disease (PD) is predominantly a disease of older age, with the prevalence of PD rising from 0.6% for those aged 65–69 years to 3.5% for those aged 85–89 years [1]. With an ageing population the number of patients with PD in the world's most populous countries is predicted to double from an estimated 4.6 million in 2005 to between 8.7 and 9.3 million by 2030, the majority of these patients will be elderly [2].
Despite an ageing population, older patients are frequently excluded from medical research on the basis of arbitrary upper age limits [3], with clinical trial populations being noted as varying significantly from the older, frailer patients seen in clinical practice [4], [5].
Given the well-recognised differences in physiology, pharmacodynamics, polypharmacy and co-morbidities seen in older patients, it is probable that the results of studies excluding the elderly may not be relevant to the patients seen in actual clinical practice; hence research findings in studies of younger individuals should not be extrapolated to the elderly. This is of particular importance in PD where the majority of patients are in the seventh decade or older.
One previous study has investigated the exclusion of older participants from PD research; this retrospective review of PD randomised control trials published between January 1966 and September 1996 found only 37% of trials included PD patients over the age of 75. While the reporting of actual numeric levels of recruitment amongst specific age groups was poor in the published studies included in this work, where this demographic data was reported, only 5.5% of trial participants were aged over 75 years [6].
To investigate to the current potential for older patients to take part in actively recruiting PD research we performed a systematic analysis of the online World Health Organisation Clinical Trials Registry. We aimed to assess the degree to which older participants are excluded from PD research on the basis of upper age limits and to investigate associations between study characteristics and exclusion by age.
Section snippets
Data source and sampling method
Our method was based on an adaptation of that recently published by the Increasing the PaRticipation of the ElDerly in Clinical Trials (PREDICT) project (http://www.predicteu.org) [7].
Information regarding ongoing PD research studies was extracted from the WHO International Clinical Trials Registry Platform (WHO-ICTRP) (http://www.who.int/ictrp/en/) on the 1st of April 2011. This database collates data from national and regional registers of clinical studies and is updated on a weekly basis
Trial characteristics
The initial search described above returned 210 results. 206 research studies were included for analysis. 2 studies were excluded as they concerned Wolff–Parkinson–White syndrome rather than PD and 2 entries were excluded as duplicate entries.
The total estimated recruitment to the studies included for analysis was 47,224 participants. Study characteristics are outlined in Table 1.
Randomised control trials made up 116 (51.5%) of the studies included, of the remaining studies the largest groups
Discussion
The exclusion of older people from clinical research is well recognised as a significant barrier to the translation of research findings to real-world clinical applications. Given that the PD patient population is predominantly elderly the recruitment of older people to PD research is critical to ensure the relevance of study findings. We aimed to assess the current potential for participation of older individuals in PD research and to identify features of studies associated with exclusion of
Declarations of interest
PR Fitzsimmons – has received educational sponsorship and/or speaker honoraria from GlaxoSmithKline, Orion Pharma and Teva–Lundbeck Pharmaceuticals
S Blayney – None
S Mina-Corkhill – None
GO Scott – None
References (22)
- et al.
Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure
Am Heart J
(2003) - et al.
Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease
J Neurol Neurosurg Psychiatry
(1997) - et al.
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Neurology
(2007) - et al.
Exclusion of elderly people from clinical research: a descriptive study of published reports
Br Med J
(1997) - et al.
Underrepresentation of patients 65 years of age or older in cancer-treatment trials
N Engl J Med
(1999) - et al.
Exclusion of elderly subjects from clinical trials for Parkinson disease
Arch Neurol
(1997) - et al.
The persistent exclusion of older patients from ongoing clinical trials regarding heart failure
Arch Intern Med
(2011) - et al.
Exclusion of older adults and women from recent trials of acute coronary syndromes
J Am Geriatr Soc
(2011) - et al.
The exclusion of the elderly and women from clinical trials in acute myocardial infarction
J Am Med Assoc
(1992) - et al.
Representation of elderly persons and women in published randomized trials of acute coronary syndromes
J Am Med Assoc
(2001)
Representation of older patients in cancer treatment trials
Cancer
Cited by (33)
Underserved groups in dysphagia intervention trials in Parkinson's disease: A scoping review
2024, Ageing Research ReviewsAge-related selection bias in Parkinson's disease research: are we recruiting the right participants?
2018, Parkinsonism and Related DisordersCitation Excerpt :There is little doubt that many published studies of PD use relatively-younger-onset patients. This has previously been highlighted regarding clinical trials [27,28], and the implications of under-representing older people in trials are clear: treatment efficacy and safety may vary by age making it difficult to assess the benefits and disadvantages of treatment in the elderly. Aetiological and prognostic research may also be substantially biased if younger-onset samples are used.
Age and perceived risks and benefits of preventive genomic screening
2018, Genetics in MedicineAge representation in antiepileptic drug trials: A systematic review and meta-analysis
2018, Epilepsy ResearchCitation Excerpt :Furthermore, subgroup analyses examining treatment effects by age were not routinely performed and reported in less than 15% of trials. Our findings are consistent with previous studies that have identified age gaps between participants in clinical trials and actual patients encountered in everyday practice, similar to findings in sporadic Alzheimer’s disease (Banzi et al., 2016), cancer (Hutchins et al., 1999; Talarico et al., 2004), heart failure (Cherubini et al., 2011; Heiat et al., 2002), osteoporosis (Beers et al., 2014), and Parkinson’s disease (Fitzsimmons et al., 2012). Though previous studies have reported a reduced use of explicit upper age limits in clinical trials of various subspecialties and in high-impact journals (McMurdo et al., 2005; Thake and Lowry, 2017; Van Spall et al., 2007), our review did not find a reduction of this practice over time in AED trials.
Benefits of subthalamic stimulation for elderly parkinsonian patients aged 70 years or older
2016, Clinical Neurology and NeurosurgeryCitation Excerpt :Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is effective in treating patients with advanced PD, typically improving their life quality [3–5]. However, elderly PD patients (age ≧ 70 years) are frequently excluded worldwide from DBS therapy [3,6,7] or related clinical trials [8] on the sole basis of upper-age limits, despite little supporting evidence. Both facts are probably not relevant to PD patients in actual clinical practice.
Regulatory development of geriatric medicines: To GIP or not to GIP?
2016, Ageing Research ReviewsCitation Excerpt :Beside increased drug costs, polypharmacy causes the geriatric patient to be at risk for adverse drug reactions, drug–drug interactions, nonadherence to drug therapy and functional decline (Shah and Hajjar, 2012). Although older patients use 30–50% of all prescription drugs, they are to a large extent excluded from clinical trials, even from trials investigating drugs for highly age-associated diseases like heart failure and Parkinson’s disease (Cherubini et al., 2010, 2011; Fitzsimmons et al., 2012; Stegemann et al., 2010). A systematic review indicated that in 38.5% of the randomized clinical trials, published in high-impact general medical journals, people aged above 65 years were excluded and in 81.3% of the trials patients with comorbidities comprising common medical conditions like kidney, infectious, cardiac, liver or hematological-oncological diseases, were absent (Kaplan et al., 2013; Van Spall et al., 2007).